Combining best-in-class AI-powered Technologies for Musculoskeletal (MSK) Imaging Workflows – ImageBiopsy Lab and Radiobotics sign Collaboration Agreement

ImageBiopsy Lab (Vienna, Austria) and Radiobotics (Copenhagen, Denmark) have teamed up to advance the use of Artificial-Intelligence (AI) supported disease diagnostics for musculoskeletal (MSK), orthopaedic, and trauma use-cases in the DACH region.

Globally, musculoskeletal conditions affect a larger population than circulatory or respiratory disorders. Despite this, diagnostic methods often remain rooted in outdated practices, relying on manual interpretation of X-rays and MRI images. These subjective and time-intensive techniques lack standardisation and depend on practitioner expertise.

Despite a growing number of MSK-specific solutions, users lack a holistic answer for diverse diagnostic needs. With their collaboration ImageBiopsy Lab and Radiobotics (both with MDR and FDA clearances) will merge their expertise and provide a single, comprehensive solution for MSK imaging, encompassing measurement, scoring, and fracture detection workflow.

Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab, explains, “Before even considering the use of AI, it’s crucial to grasp physicians’ diagnostic workflow and needs. For this purpose we’ve closely collaborated with leading MSK radiologists, orthopaedics, and traumatologists over the past years. We’re committed to revolutionizing the entire MSK diagnostic value chain for practitioners, patients, and healthcare systems.

We see Radiobotics as the logical partner to offer best in class solutions for MSK conditions diagnostics, from measurements and scoring to fracture detection. Our collaboration marks the next AI-powered workflow integration phase.

Mads Jarner, CEO and Co-founder of Radiobotics, notes, “As MSK AI solutions gain traction in clinical workflows, providing clinics with integrated and comprehensive options becomes vital. We’re thrilled to collaborate with ImageBiopsy Lab to facilitate access to our market-leading solutions. Leveraging ImageBiopsy Lab’s expertise and network in German-speaking regions, we’re excited to introduce our RBfracture™ fracture detection solution in this area initially, with potential expansion to other regions.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version